PUBLICATION

The tumor suppressor gene lkb1 is essential for glucose homeostasis during zebrafish early development

Authors
Kuang, X., Liu, C., Fang, J., Ma, W., Zhang, J., Cui, S.
ID
ZDB-PUB-160608-6
Date
2016
Source
FEBS letters   590(14): 2076-85 (Journal)
Registered Authors
Kuang, Xia, Liu, Chao, Ma, Weirui, Zhang, Jian
Keywords
Lkb1, early development, gluconeogenesis, glycolysis, zebrafish
MeSH Terms
  • Animals
  • Glucose/genetics
  • Glucose/metabolism*
  • Glycolysis/physiology*
  • Protein Serine-Threonine Kinases/biosynthesis
  • Protein Serine-Threonine Kinases/genetics
  • Protein Serine-Threonine Kinases/metabolism*
  • Tumor Suppressor Proteins/genetics
  • Tumor Suppressor Proteins/metabolism*
  • Up-Regulation/physiology
  • Zebrafish/genetics
  • Zebrafish/metabolism*
  • Zebrafish Proteins/genetics
  • Zebrafish Proteins/metabolism*
PubMed
27264935 Full text @ FEBS Lett.
Abstract
The liver kinase B1 (LKB1) is encoded by tumor suppressor gene STK11, which is mutated in Peutz-Jeghers Syndrome patients. Lkb1 plays indispensable roles in energy homeostasis. However, how Lkb1 regulates energy homeostasis in vivo remains to be fully understood. We found that inactivation of zebrafish Lkb1 upregulates pyruvate dehydrogenase kinase 2 expression and inactivates pyruvate dehydrogenase complex by increasing phosphorylation of pyruvate dehydrogenase. As a result, glycolysis is significantly enhanced as indicated by increased lactate production, which resembles the Warburg effect in cancer cells. Inhibition of Pdk2 in lkb1 mutants with Dichloroacetate, a promising anti-cancer drug, rescued the lactate production to wild-type level, suggesting the lkb1 mutant may be used to screen compounds targeting aerobic glycolysis in cancer therapy. This article is protected by copyright. All rights reserved.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping